Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 497 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Elevated Cardiovascular Risk Clear all
Completed No phase listed Observational

Atrial Fibrillation Screening in Nursing Homes

NCT03860246
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Portable ECG monitor
Diagnostic Test
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
Not listed
Enrollment
245 participants
Timeline
2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 30, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Results available

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

NCT02957682
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Praluent (Alirocumab), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
2,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
73
States / cities
Auburn, Alabama • Birmingham, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Sep 30, 2026, 7:27 PM EDT
Completed Phase 1 Interventional

Metro Atlanta Heart Disease Study - II (MAHDS II)

NCT01235702
View directory record Official record
Conditions
African Americans With Hypertension.
Interventions
12-week lifestyle modification
Behavioral
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
21 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Sep 30, 2026, 7:27 PM EDT
Not listed No phase listed Observational

Utilizing Technology for Optimization of Pain Management and Mobilization in High Risk Cardiac Surgical ICU Patients

NCT04146727
View directory record Official record
Conditions
Transplant; Failure, Heart, Heart Failure, Congestive, Lung Transplant Failure
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
168 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 30, 2026, 7:27 PM EDT
Completed No phase listed Observational

CHOICE: Carotid Stenting For High Surgical-Risk Patients

NCT00406055
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
18,855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Sep 30, 2026, 7:27 PM EDT
Terminated Not applicable Interventional

Expanding Access to Care Through Telemedical Support for Vital Sign Monitoring in High-risk Patients With Cancer

NCT06364748
View directory record Official record
Conditions
Hypertension
Interventions
Cellular enabled blood pressure cuff, Standard of Care Cuff
Device
Lead sponsor
West Michigan Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Sep 30, 2026, 7:27 PM EDT
Terminated Phase 3 Interventional Results available

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

NCT04811092
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, Placebo
Drug · Other
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
28
States / cities
Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 30, 2026, 7:27 PM EDT
Recruiting Not applicable Interventional

A Dietary Study for People With Multiple Myeloma

NCT07226609
View directory record Official record
Conditions
Multiple Myeloma
Interventions
nutrition counseling and coaching, dietary guidelines, research dietitian visit, Questionnaires, Frozen pre-prepared meals
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 30, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

NCT03872401
View directory record Official record
Conditions
Coronary Heart Disease (CHD)
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years to 79 Years
Enrollment
12,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
145
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 30, 2026, 7:27 PM EDT
Active, not recruiting Not applicable Interventional Results available

Portico Next Generation Approval Study

NCT04011722
View directory record Official record
Conditions
Symptomatic Severe Aortic Stenosis
Interventions
Portico™ NG (Navitor) Valve and FlexNav™ Delivery System, Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
21
States / cities
Los Angeles, California • Thousand Oaks, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 30, 2026, 7:27 PM EDT
Completed Not applicable Interventional Results available

XIENCE 28 USA Study

NCT03815175
View directory record Official record
Conditions
Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions
XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 30, 2026, 7:27 PM EDT
Completed Not applicable Interventional

Early Feasibility Study of the Supira System in Patients Undergoing HRPCI

NCT06087575
View directory record Official record
Conditions
Coronary Artery Disease, High-risk Percutaneous Coronary Intervention, Interventional Cardiology
Interventions
Supira System
Device
Lead sponsor
Supira Medical
Industry
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Sacramento, California • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 30, 2026, 7:27 PM EDT
Completed No phase listed Observational

Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study

NCT04304105
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Artery Disease
Interventions
Not listed
Lead sponsor
LimFlow, Inc.
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Timeline
2020 – 2022
U.S. locations
24
States / cities
Los Angeles, California • Torrance, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 30, 2026, 7:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cocoa and Endothelial Function in Adults With Elevated BMI

NCT00538083
View directory record Official record
Conditions
Cardioprotection
Interventions
Chocolate
Other
Lead sponsor
Griffin Hospital
Other
Eligibility
30 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 30, 2026, 7:27 PM EDT
Completed Phase 2 Interventional

Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma

NCT00847639
View directory record Official record
Conditions
Multiple Myeloma
Interventions
lenalidomide
Drug
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Duarte, California • Tampa, Florida • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Sep 30, 2026, 7:27 PM EDT
Completed No phase listed Observational

Risk-score Based ICU Triage

NCT03390270
View directory record Official record
Conditions
Non-ST Elevation Myocardial Infarction (nSTEMI)
Interventions
Admission with NSTEMI
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 30, 2026, 7:27 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

NCT00963872
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
cyclophosphamide, fludarabine phosphate, Total body irradiation, Umbilical cord blood unit with C3a fragment, Unmanipulated UCB Unit
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 30, 2026, 7:27 PM EDT
Not listed Not applicable Interventional

Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis

NCT02657707
View directory record Official record
Conditions
Carotid Artery Stenosis
Interventions
Roadsaver™ Carotid Artery Stent Device, Nanoparasol® Embolic Protection System
Device
Lead sponsor
Microvention-Terumo, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
37
States / cities
Phoenix, Arizona • Prescott, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 30, 2026, 7:27 PM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

NCT06768489
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
Interventions
JNJ-79635322, Daratumumab, Pomalidomide, Lenalidomide
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Denver, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 7:27 PM EDT
Recruiting Not applicable Interventional

Innovative Approaches to Hypertension Management in High-Risk Emergency Department Populations

NCT07539597
View directory record Official record
Conditions
Asymptomatic Hypertension
Interventions
Community Health Worker engagement
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 30, 2026, 7:27 PM EDT
Completed Not applicable Interventional Results available

Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients

NCT02701582
View directory record Official record
Conditions
Intracranial Aneurysm, Brain Edema, Scoliosis, Surgery
Interventions
Phenylephrine, Epinephrine, Albumin, Voluven, Normal Saline, Packed Red Blood Cells, FloTrac Monitor
Drug · Other · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
15 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Sep 30, 2026, 7:27 PM EDT
Recruiting Not applicable Interventional

WIREDUP: Wearable Insoles for Recurrent Diabetic Ulcer Prevention

NCT05950659
View directory record Official record
Conditions
Diabetes, Peripheral Neuropathy, Diabetic Foot, Diabetic Foot Ulcer
Interventions
Orpyx Sensory Insole System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 30, 2026, 7:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

CAUSE Trial: Patient Specific-Cellular Characterization of Fibromuscular Dysplasia and High-Risk Atherosclerotic Endothelium

NCT01808729
View directory record Official record
Conditions
Fibromuscular Dysplasia, Early Onset CAD
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 30, 2026, 7:27 PM EDT
Completed Phase 2 Interventional Results available

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

NCT01131169
View directory record Official record
Conditions
Multiple Myeloma
Interventions
busulfan, melphalan and fludarabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 72 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 30, 2026, 7:27 PM EDT